Nuo Therapeutics, Inc. issued shares of the Company's common stock of warrant to five lenders (collectively, the 'Lenders') for issued as loan fees and for accrued interest.
“On May 29, 2026, the closing date of the Interim Funding, and pursuant to the Interim Loan Agreement, the Company (a) issued to each Lender warrants, a portion of which are subject to vesting provisions, to purchase shares of the Company’s common stock, (b) cancelled certain warrants previously issued pursuant to the Initial Funding, and (c) again agreed to issue additional warrants to each Lender in the Interim Funding to purchase shares of the Company’s common stock as payment for accrued interest under the Notes.”
Debt Financings
Nuo Therapeutics, Inc. incurred credit facility of aggregate principal amount of up to $2.0 million with $1,000,000 previously funded on January 23, 2026, $675,000 funded with Scott M. Pittman and four other lenders at annual rate of 12% (increased from 10% on prior notes) maturing December 31, 2028.
“On May 29, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Loan and Security Agreement (the “Interim Loan Agreement”) with five lenders (collectively, the “Lenders”).”
Material Agreements
Nuo Therapeutics, Inc. amended Amended and Restated Loan and Security Agreement with five lenders valued at $2.0 million (effective 2026-05-29).
“On May 29, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Loan and Security Agreement (the “Interim Loan Agreement”) with five lenders (collectively, the “Lenders”).”
Earnings Releases
Nuo Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue approximately $1.3 million.
“results for the first quarter ended March 31, 2026 and provided an operational and business update. First Quarter 2026 Financial Summary ● Total revenues of approximately $1.3 million (including approximately $1,224,000 of product revenues) increased 169% over the 2025 first quarter and 20% over last year’s fourth quarter ● Aurix branded product revenues were”
Equity Issuances
Nuo Therapeutics, Inc. issued warrant to four lenders (collectively, the 'Lenders').
“On January 23, 2026, the closing date of the Initial Funding, and pursuant to the Loan Agreement, the Company issued to each Lender warrants, some of which are subject to vesting provisions, to purchase shares of the Company’s common stock”
Debt Financings
Nuo Therapeutics, Inc. incurred credit facility of aggregate principal amount of up to $1.6 million with four lenders (including Scott M. Pittman and Paul Anthony Jacobs) at annual rate of 10% maturing December 31, 2028.
“On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million with (a) $1.0 million funded on the initial closing date (the “Initial Funding”) and (b) $600 thousand to be funded, if requested in advance by the Company and subject to closing conditions, on September 30, 2026 (the “Second Funding”).”
Material Agreements
Nuo Therapeutics, Inc. entered into Loan and Security Agreement with four lenders (collectively, the "Lenders") valued at up to $1.6 million (effective 2026-01-21).
“On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million”
Material Agreements
Nuo Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $962,500 (effective 2023-12-18).
“On December 18, 2023, Nuo Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of December 8, 2023, with certain accredited investors for the sale of 1,925,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a price of $0.50 per share for gross proceeds of $962,500 (the “Private Placement”).”
Shareholder Votes
Nuo Therapeutics, Inc. shareholders approved Ratification and approval of the 2016 Omnibus Incentive Compensation Plan, as amended at the 2022-12-02 meeting.
“For Withheld Abstain 5. To ratify and approve the Company's 2016 Omnibus Incentive Compensation Plan, as amended 26,188,825 7,988 505,954”
Shareholder Votes
Nuo Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2022-12-02 meeting.
“One Year Two Years Three Years Abstain 4. To approve, on an advisory basis, the frequency of the advisory vote on executive compensation 2,389,764 37,874 23,767,794 507,335”
Shareholder Votes
Nuo Therapeutics, Inc. shareholders approved Advisory vote to approve executive compensation at the 2022-12-02 meeting.
“For Withheld Abstain 3. To approve, on an advisory basis, the compensation of the Company's named executive officers 26,692,397 5,370 5,000”
Shareholder Votes
Nuo Therapeutics, Inc. shareholders approved Ratification of the appointment of Marcum LLP as independent registered public accounting firm for fiscal year 2022 at the 2022-12-02 meeting.
“For Withheld Abstain 2. To ratify the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022 27,697,944 1,074 0”
Shareholder Votes
Nuo Therapeutics, Inc. shareholders approved Election of four directors to serve on the Board of Directors at the 2022-12-02 meeting.
“1. Election of Directors For Withheld Broker Non-Votes David E. Jorden 26,699,444 3,323 996,251 C. Eric Winzer 26,198,490 504,277 996,251 Scott M. Pittman 26,199,444 503,323 996,251 Paul D. Mintz 26,199,444 503,323 996,251”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.